D.E. Shaw & Co
MYGN icon

D.E. Shaw & Co’s Myriad Genetics MYGN Stock Holding History

D.E. Shaw & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-19,600
Closed -$506K – 3549
2017
Q2 		$506K Sell
19,600
-800
-4% -$17K ﹤0.01% 2808
2017
Q1 		$392K Buy
+20,400
New +$361K ﹤0.01% 2849

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's MYGN Position: Q2 2026 in Review

D.E. Shaw & Co increased its Myriad Genetics (MYGN) stake by 1.8% in Q2 2026, buying an estimated $374K and bringing the position to 4,582,083 shares worth $26.2M. The position accounts for 0.01% of the portfolio, ranked #1119.

D.E. Shaw & Co first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $179M in Q3 2018. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • D.E. Shaw & Co held 4,582,083 shares of Myriad Genetics worth $26.2M as of Q2 2026.
  • D.E. Shaw & Co bought 82,359 Myriad Genetics shares in Q2 2026, an estimated $374K.
  • Myriad Genetics made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1119 holding.
  • D.E. Shaw & Co first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
  • D.E. Shaw & Co's Myriad Genetics position peaked at $179M in Q3 2018.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.